Victory Capital Management Inc. Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Victory Capital Management Inc. raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,924,763 shares of the medical equipment provider’s stock after buying an additional 383,570 shares during the quarter. Victory Capital Management Inc. owned about 0.97% of Zimmer Biomet worth $198,617,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ZBH. Rakuten Investment Management Inc. acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth $37,307,000. Sector Gamma AS increased its holdings in Zimmer Biomet by 28.0% in the 3rd quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock valued at $11,178,000 after buying an additional 24,847 shares during the period. Resona Asset Management Co. Ltd. lifted its position in shares of Zimmer Biomet by 5.7% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 67,915 shares of the medical equipment provider’s stock worth $6,197,000 after buying an additional 3,634 shares during the period. SG Americas Securities LLC lifted its holdings in Zimmer Biomet by 29.2% during the 3rd quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock valued at $6,019,000 after purchasing an additional 13,812 shares during the last quarter. Finally, Border to Coast Pensions Partnership Ltd increased its holdings in Zimmer Biomet by 6.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after purchasing an additional 22,104 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. Stifel Nicolaus set a $110.00 price target on shares of Zimmer Biomet in a research report on Wednesday, November 5th. Robert W. Baird reaffirmed a “neutral” rating and set a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Barclays cut their price objective on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research report on Thursday, February 12th. Citigroup reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, Canaccord Genuity Group cut their price target on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Trading Down 1.5%

Shares of NYSE ZBH opened at $97.99 on Wednesday. The firm’s 50 day moving average price is $91.89 and its 200-day moving average price is $95.81. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The company has a market cap of $19.17 billion, a PE ratio of 27.68, a P/E/G ratio of 2.03 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a 52-week low of $84.59 and a 52-week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the previous year, the company posted $2.31 EPS. The firm’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.